Medanta IPO

Global Health Limited is one of the major private multi-specialty tertiary care facilities, in the North and East of India. Medanta IPO will hit the market in 03 November 2022.

About Global Health (Medanta)

According to the CRISIL Report, their main specialities include cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopaedics, liver transplant, and kidney and urology.

They have a network of four hospitals now in operation (Gurugram, Indore, Ranchi, and Lucknow), one hospital under construction with an operating outpatient centre (Patna), and one hospital slated for development (Noida) under the “Medanta” brand.

They currently provide healthcare facilities in over 30 medical specialities and employ over 1,100 doctors who are supervised by highly experienced department directors. Their operating facilities cover 3.7 million square feet and have 2,176 installed beds.

Operations

They steadily increased the number of their beds to 2,176 installed beds as of March 31, 2021, to serve Indian and foreign patients.

They expanded to Indore (175 installed beds as of March 31, 2021), Ranchi (200 installed beds as of March 31, 2021), and Lucknow (410 installed beds as of March 31, 2021, with ability to accommodate up to 900 beds) in 2014, 2015, and 2019, respectively, after opening our flagship hospital in Gurugram (1,391 installed beds as of March 31, 2021).

Their Patna hospital’s outpatient department is now functioning, and the remainder of the hospital is anticipated to open in Fiscal 2022, with a target of 300 installed beds.

Clinical Research and Academics

Their clinical research facility, which opened in 2009, is another driving reason behind their excellent level of treatment. In 2017, they launched “The Medanta Institutional Tissue Repository” to support biomarker and other tissue-based research.

During 2020-21, doctors affiliated with their hospitals produced 325 peer-reviewed indexed journal articles.

They have ongoing research projects and are now collaborating with Qure.ai to create artificial intelligence algorithms with the goal of enhancing productivity and improving medical diagnosis accuracy.

With over 100 authorised seats, they offer 36 specialties under the Diplomate of National Board (“DNB”) and Fellowship in National Board programmes.

Medanta IPO

Global Health Limited (Medanta), headquartered in Delhi has submitted Draft Red Herring Prospectus(DRHP) to Securities and Exchange Board of India(SEBI) for initial public offering (IPO) of INR 500 crores Value equity and 48,440,000 equity share on 29 September 2021.

The offer includes 500 crores value fresh equity shares and there is an offer for sale (OFS) of  48,440,000 equity shares by the promoters mentioned in the DRHP. They are not also looking to for any pre-ipo placement.

They are now waiting for approval from Securities and Exchange Board of India(SEBI) to float the initial public offering (IPO) in the market.

Financials Trends

Particulars	For the year/period ended ( in Cr.)
		31-Mar-21	31-Mar-20	31-Mar-19
Total Assets		2,694.10	2,666.29	2,430.00
Total Revenue		1,478.16	1,544.27	1,505.99
Profit After Tax		28.80	36.33	51.30

Basic and Diluted Earnings Per Share

Financial Period	Basic EPS (in INR)	Diluted EPS (in INR)	Weight
Financial Year 2021	1.15	1.14	3
Financial Year 2020	1.45	1.44	2
Financial Year 2019	2.06	2.04	1
Weighted Average	1.40	1.39

Objects of the Issue

• Prepayment / repayment of all or a portion of the outstanding borrowings of the company to be availed on consolidated basis.
• To meet common corporate objectives.

Basis of the offer

The fundamental factors that go into determining the Offer Price:

• Leading tertiary and quaternary care provider in India, with a reputation for clinical excellence, particularly in complex situations.
• Clinical research and academics are the main focus areas.
• ‘Doctor-led’ hospitals are run by some of the greatest and most experienced doctors in the industry.
• Large-scale hospitals with world-class infrastructure and cutting-edge medical technologies and equipment.
• Strong operational and financial performance in the past.
• Focus on underserved areas with dense populations and presence in big states’ top or capital cities.
• Existing facility expansion and diversification into new services, including digital health, are also possibilities.
• Senior management team with a vast experience..

Medanta IPO Peer Comparison

S. No.	Face Value	Company Name	PE
1	5	Apollo Hospitals Enterprise Limited	410.71
2	10	Fortis Healthcare Limited	N/A
3	10	Max Healthcare Institute Limited	N/A
4	10	Narayana Hrudayalaya Limited	N/A

Note 

• This has been declared as N.A. since the P/E ratio is negative.
• Industry Peer data was gathered from the following sources: All of the financial data for the listed industry peer mentioned above comes from the company’s annual report for the fiscal year ending March 31, 2021, which was filed with stock exchanges.

Medanta IPO Details

IPO Opening Date	03 November 2022
IPO Closing Date	07 November 2022
Issue Type	Book Building
Face Value	2 per share
IPO Price	319 to 336 per equity share
Market Lot	44
Min Order Amount	14,784
Listing At	BSE, NSE
Issue Size	2,205.57 Crore
Fresh Issue	500 crore
Offer for Sale	48,440,000 Equity Shares

Medanta IPO Date

Medanta IPO opening date is 03 November 2022, and the closing date is 07 November 2022. The Medanta IPO issue may list in 16 November 2022.

IPO Opening Date	03 November 2022
IPO Closing Date	07 November 2022
Basis of Allotment Date	11 November 2022
Initiation of Refunds	14 November 2022
Credit of Shares to Demat Account	15 November 2022
IPO Listing Date	16 November 2022

Basis of Allotment

Type	% of Offer	Basis of Allotment
Qualified Institutional Buyer	50	Roughly  equivalent
Non Institutional Investor	15	Roughly  equivalent
Retail	35	Minimum level of 1 lot, based on availability, for every shareholder.

Medanta IPO Allotment Status

Allotment of equity stocks subject to the Fresh Issue and transfer of the Promoter Selling Shareholders’ OFS Stocks to the winning Bidders subject to the Offer for Sale. Nevertheless, the status of the allotment has yet to be revealed.

Here, you can find the Allotment Status of Medanta IPO.

Medanta IPO GMP

Medanta IPO Grey Market Premium is 0. You can check out GMP of Other IPOs on below Links:

Date	GMP (in Rs)	Subject to Sauda	Kostak (in Rs)
November 2022
November 2022
November 2022
November 2022
November 2022
November 2022
November 2022
November 2022
November 2022
November 2022
November 2022
November 2022

Check Out the GMP of all Other IPOs

IPO Grey Market Premium

Medanta IPO Review

Medanta IPO review will depend on the price band which will be announced after SEBI approval. Whenever it will be announced we will update you regarding review of Medanta IPO is good or bad.

Medanta IPO Risk

• Strict regulations aimed at slowing the spread of Covid-19 have had and may continue to have a detrimental impact on their company.
• Doctors, nurses, and other healthcare workers are extremely important to their.
• Medical and legal dangers, as well as unfavourable publicity, are inherent in the functioning of medical institutions.
• Some of the property parcels on which their hospital facilities and clinics are located are neither owned nor leased to them on a long-term basis.
• Regulatory reforms in the healthcare business, as well as the resulting uncertainties, may have a negative impact on their company.
• They rely on third-party suppliers and subcontractors, as well as relationships with third-party payers and insurers, all of which may be cancelled.

Other Threats

• To carry on their company activities, they rely on bank or financial institution financing.
• Their capacity to continue operations might be affected if their medical or other equipment fails or malfunctions.
• They are bound by regulations for the supply of free beds, which are subject to change and may have a negative impact on their profitability.
• They have pending lawsuit against them, their directors, subsidiaries, and promoter, the outcome of which might have a negative impact on their company.
• Any rise in their contingent liabilities, or their realisation, might have a negative impact on their financial situation.
• Delays in collecting payment from third parties for outstanding debts, as well as any lengthy delays, may have an impact on their operations.

Design and Operations

In both design and operations, they lay a strong emphasis on infection control techniques (e.g. dedicated air-handling units for all operating theatres and ICUs, dedicated transplant rooms with positive pressure and isolation rooms in each ICU).

Given the significant procedure-orientation of clinical work, they retain a high number of operating theatres, procedure rooms, and ICUs relative to overall bed strength, and modular architecture across all units to permit scaling up and down as per occupancy and specialist requirements.

They ‘ve invested in cutting-edge medical technology and equipment to ensure that their physicians and medical personnel have all they need to offer the best possible treatment.

Growth

As of March 31, 2021, they have grown to hospitals with 2,176 installed beds in five locations. They think that robust patient numbers, cost efficiency, and a diverse income stream across medical specialties have consistently generated good operational and financial success.

Their commitment to patients has helped them improve the “Medanta” brand over the years, and they feel their patients have placed a great level of faith in them. In 2019, 2020, and 2021, the total number of patients was 1,370,781, 1,389,460, and 1,178,230, respectively.

Their newest hospitals have benefitted from the “Medanta” brand’s established image and trustworthiness, allowing them to capitalise on their potential for development.

Medanta IPO Brokerage views

• Yes Securities : Not Updated
• Choice Brokering: Not Updated
• Axis Securities: Not Updated
• IIFL Securities: Not Updated
• Trade swift: Not Updated
• Anand Rathi : Not Updated
• ICICI Securities: Not Updated

Medanta IPO Subscription Status

Date	Day	QIB	NII	Retail	Employees	Total Subscription
November 2022	1
November 2022	2
November 2022	3

Management

Dr. Naresh Trehan, a world-renowned cardiovascular and cardiothoracic surgeon, established Global Health Limited. In honour of his remarkable service to medicine, he has been given the coveted Padma Bhushan and Padma Shri, India’s third and fourth highest civilian awards, as well as the BC Roy medal.

Dr. Trehan is the heart and soul of their hospitals. They aim to provide world-class healthcare by building institutions of excellence that combine medical treatment, teaching, and research while also keeping medical services affordable for patients.

In the years 2020 and 2021, their Gurugram hospital was named the finest private hospital in India for two years in a row.

Promoters

• Naresh Trehan

Promoter’s Holding

Pre Issue Share Holding	35.04%
Post Issue Share Holding